Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Any feedback appreciated.
Hi Freddy
Was an interesting webinar . Suzy looked very comfortable and relaxed. So much so that I think she’s going nowhere .
If she’s still CEO at Agm ,with quiet months of July and August to come then she’s Ceo for a lot longer .
It’s plainly obvious we need her to hand over to Cathy ,Adam or another internal candidate as it’s going to be near impossible to raise £2m with Suzy and Kevin still there .
No one will believe their empty promises . No one believes a word they have to say about Theoremx.
Would you part with a penny to pay their wages knowing in a years time another £2m will be needed cos no way is £2m of revenue coming in within 12 months.
So I think large shareholders need to force change ..TODAY.
Good luck all. Hope I’m very wrong but those are my thoughts. .Webinar showed me no urgency at all. What a shame.
Best
Nick
So, in short, they came across as the arrogant skcirp that they are. That seems to be the market reaction anyway.
Nice questions you added Nick . Are you wishing you would of added temp Ceo ?
Should have sacked the pair of them with the requisition
Just watched the webinar. I can understand why they have changed the mission statement and omitted any reference to how ValiRx 'accelerates' anything. The discussion at the end surrounding a CLX deal not being likely in 2024 means they still work at industry standard pace.
I'm a bit bothered by the reliance on TRx again, having watched the webinar. I don't believe the lab will contribute to income sufficiently enough to stretch out a placing beyond more than a couple of months.
Adrian suggested that the 201 conclusion will be on the new CEO's plate. Make of that what you will.
The 201 deal is anticipated to complete this year based on the presentation. I think it is important to recognise it was Adrian and the other board member who is also an AIM CEO asking TRX all the questions so clearly they think it is fairly likely. Nothing confirmed based on past promises but quietly confident. Judging on the EUDA market cap and rise I would think it is highly likely.
They have cash until H2 2025 but a few months extra from lab revenue would be amazing but the hope is 201 concludes soon. Clearly at this market cap we will get a significant gap up at these prices if it concludes.
They stated we will get CLX updates this year. The more the cash runway increases next year the greater the chance of an early preclinical deal early next year. By then hopefully with all the RNS that we have due our market cap will be above 10/15 million so a 2 million raise at much higher prices once delivery starts coming through is not an issue.
We also have potentially 3 evaluation outcomes before then as well and Adam was thinking each one at SPV is valued around 10 million to the company so plenty of upside from here.
Ken has strung everyone along for over three years now. At some point they are going to have to stop believing what he is telling them. He must've been the one who told them that funding would be in place before the end of 2021. He is unreliable. Full stop.
That is what you see but in reality when you are inside you ask more intelligent questions and base decisions of facts and evidence not on opinions from the outside. They would have discussed where the financing is, how much already raised, what plans are etc. It is not as simple as we are confident so all that would have been done and they concluded to allow them to carry on. We have to trust what they say as it was shareholders who backed change now when new individuals give it the backing then I don't understand the complaining. Why ask for change if you trust the new people?
ValiRx is now back to being 100% reliant on a person, whom has been proven to be unreliable for a period of over three years, to avoid another low ball, bucket shop placing.
I think I need to hear a bit more than 'confidence' that it will conclude now. That's worn too thin now.
Based on a start date of October 2022 and the stage lengths referenced in the webinar, we are looking at a deal being announced for CLX001 anywhere from April 2025 through to October 2026.
If you exclude the income from the lab (🤣), that's a long time between drinks.
Obviously I've not considered 401 in this as I've no confidence in Ambrose either.
To be fair to SD she did say "Although the sub-license of VAL201 to TheoremRx has taken longer to complete than initially anticipated, during the course of the past four months, ValiRx has been continuing to conduct due diligence on TheoremRx and its scientific plans and remains confident that it is well placed to conduct the ongoing development of the VAL201 programme. Our due diligence procedures are now complete and during this final extension of exclusivity we will continue to provide scientific support to TheoremRx's trial start-up processes to ensure no further delays are encountered."
Problem is, that was in March 2022. Good job they haven't encountered any further delays then...
Just watched the webinar...I think Adrian came across well and seems to be a good asset.. .. Good question put across by Nick, nick and direct so fair play to him .. I'd hedge a bet that the CEO will be internal .. it shouldn't be Kathy tho as suzy states that she's ( kathy) a better scientist than herself . I would have put them.on the spot and asked how much have Theoremrx raised so far to date ...
They keep using the excuse that it affects the ability of TRx to complete the funding if they were to divulge such info.
Kev C had it nailed on (in August 2020) when he said completion of a deal for 201 was "on the critical path" for the success of the company.
Rat,
'Good job they haven't encountered any further delays then...'
To be fair, I am not aware of there ever having been a delay in paying the Directors. They seem to know what to prioritise.